July

5

  View Web Version                Facebook                Twitter                rettsyndrome.org

Rett Community Researchers:

We are now accepting Letters of Intent for the Basic Research program and the second cycle of the 2012 Translational Research program. Deadline date: August 1st
Please visit the IRSF Grants Opportunities page on the IRSF web site for more information.

We would also like to point out opportunities from the NIH guide.

From the National Center for Advancing Translational Sciences (NCATS), there is a Program Announcement and two associated RFAs for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules. NCATS seeks to develop a therapeutics discovery pilot program that will explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. The X02 pre-application is the first step in the application process for RFA-TR-12-004 and RFA-TR-12-005; applicants must read both of the companion Funding Opportunity Announcements.

An RO1 funding opportunity was also announced from the National Institute of Mental Health (NIMH), which seeks research grant applications designed to develop innovative ways of understanding mental disorders through classifying patients in clinical studies on the basis of experimental research criteria rather than traditional diagnostic categories.

Finally, we would like to make you aware of an available webinar for “Alternative Funding for Drug Development through the NIH Blueprint for Neurotherapeutics” available through the Neurotechnology Industry Organization (NIO) and the National Institute of Neurological Disorders & Stroke (NINDS), Office of Translational Research. The webinar on the NIH Blueprint Neurotherapeutics Program to be held Tuesday, July 10th, 2012 at 1:00 pm EST.



Jun 15 NIH Guide

A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (X02)
    (PAR-12-203)
  • National Center for Advancing Translational Sciences
  • Application Receipt Date(s): August 14, 2012



Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)
    (RFA-TR-12-004)
  • National Center for Advancing Translational Sciences
  • Application Receipt Date(s): December 17, 2012



Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)
    (RFA-TR-12-005)
  • National Center for Advancing Translational Sciences
  • Application Receipt Date(s): December 17, 2012



Jun 29 NIH Guide

Dimensional Approaches to Research Classification in Psychiatric Disorders (R01)
    (RFA-MH-13-080)
  • National Institute of Mental Health
  • Application Receipt Date(s): October 22, 2012



A note from the families who attended Family Conference at the
7th World Rett Syndrome Congress to all Rett syndrome researchers.



IRSF is the world's leading private funder of basic, translational and clinical Rett syndrome research, funding over $26M in high-quality, peer-reviewed research grants and programs to date. Annually, IRSF hosts the world's largest gathering of global Rett researchers and clinicians to establish research direction and priorities while exchanging ideas and the most recent information. IRSF is the most comprehensive non-profit organization dedicated to providing thorough and accurate information about Rett syndrome, offering informational and emotional family support and stimulating research aimed at accelerating treatments and a cure for Rett syndrome and related disorders. IRSF has earned Charity Navigator's most prestigious 4-star rating. To learn more about IRSF and Rett syndrome, visit www.rettsyndrome.org or call IRSF at 1-800-818-7388 (RETT).

Designed by Songswift: global village solutions
© 2012 All Rights Reserved